PowderJect signs $90 million agreement with Ares-Serono
This article was originally published in Clinica
Executive Summary
Drug delivery company PowderJect Pharmaceuticals stands to gain up to $90 million following a worldwide, exclusive agreement with the Ares-Serono group to develop its needleless dry powder injection device, the PowderJect System. The deal covers the delivery of undisclosed therapeutic proteins from Ares-Serono - probably in the company's chief areas of reproductive health and immunology. PowderJect's shares immediately rose by 20% to 850p. As Clinica went to press, shares were valued at 887.5p.